Physician profile
Brian E Persing
NPI 1538189543
$262,631.23
in general payments reported to CMS, 2019-2025
75 companies · $64K in 2025
The $64K reported for 2025 was more than what 96% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $28K · 2021: $37K · 2022: $38K · 2023: $40K · 2024: $36K · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $93K · Consulting Fee: $29K · Food and Beverage: $9,563 · Travel and Lodging: $7,305 · Education: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $93,451.91 |
| Consulting Fee | $28,723.00 |
| Food and Beverage | $9,562.86 |
| Travel and Lodging | $7,305.35 |
| Education | $372.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $115,853.44 | 2019-2025 | Imfinzi, Tagrisso, Enhertu |
| Regeneron Healthcare Solutions, INC. | $58,888.38 | 2022-2025 | Libtayo, Lynozyfic |
| Jazz Pharmaceuticals INC. | $23,389.01 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $17,047.12 | 2019-2025 | Opdivo, Opdualag |
| Genentech USA, INC. | $11,965.54 | 2019-2025 | Polivy, Tecentriq, Lunsumio |
| Janssen Biotech, INC. | $10,850.53 | 2019-2025 | Rybrevant, Carvykti, Tecvayli |
| Regeneron Pharmaceuticals, INC. | $4,538.95 | 2022-2025 | Libtayo |
| Mirati Therapeutics, INC. | $3,676.19 | 2023-2024 | Krazati |
| Incyte Corporation | $2,518.65 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Celgene Corporation | $2,035.84 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Daiichi Sankyo INC. | $2,030.98 | 2019-2025 | Datroway, Enhertu, Injectafer |
| Novartis Pharmaceuticals Corporation | $1,457.94 | 2019-2025 | |
| Lilly USA, LLC | $1,366.31 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Merck Sharp & Dohme LLC | $853.98 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Eisai INC. | $703.99 | 2019-2025 |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $675.61 | 2019-2025 | |
| Genzyme Corporation | $398.48 | 2019-2025 | |
| Amgen INC. | $333.85 | 2019-2022 | |
| Astellas Pharma US INC | $270.90 | 2019-2025 | Padcev, Vyloy |
| Takeda Pharmaceuticals U.S.A., INC. | $254.46 | 2019-2025 | Iclusig, Alunbrig, Ninlaro |
| Abbvie INC. | $204.80 | 2019-2025 | |
| Exelixis INC. | $160.25 | 2019-2025 | Cabometyx |
| Gilead Sciences, INC. | $135.86 | 2019-2024 | Trodelvy |
| Stemline Therapeutics INC. | $127.69 | 2023-2025 | Orserdu |
| Blueprint Medicines Corporation | $125.16 | 2020-2024 | Ayvakit |
| Geron Corporation | $123.08 | 2025 | Rytelo |
| Ethicon INC. | $121.42 | 2020 | |
| Acceleron Pharma, INC. | $110.81 | 2020-2021 | |
| Rigel Pharmaceuticals, INC. | $101.26 | 2019-2024 | Rezlidhia, Tavalisse |
| Glaxosmithkline, LLC. | $99.09 | 2022-2024 | Jemperli, Ojjaara, Zejula |
| Bayer Healthcare Pharmaceuticals INC. | $98.98 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $93.81 | 2023-2025 | Fotivda |
| Sobi, INC | $93.47 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.91 | 2019-2025 | Gilotrif |
| Pharmacyclics LLC, An Abbvie Company | $89.45 | 2019 | |
| Tersera Therapeutics LLC | $88.10 | 2023-2025 | Zoladex |
| Beigene USA, INC. | $84.54 | 2022-2023 | Brukinsa |
| Pharmaessentia USA Corporation | $82.98 | 2023-2025 | Besremi |
| Beone Medicines USA, INC. | $81.37 | 2025 | Brukinsa, Tevimbra |
| Emd Serono, INC. | $78.03 | 2019-2025 | |
| Taiho Oncology, INC. | $77.82 | 2022-2024 | |
| Array Biopharma INC | $75.36 | 2022-2025 | Xalkori, Lorbrena, Braftovi |
| Ipsen Biopharmaceuticals, INC | $68.84 | 2019-2020 | |
| Deciphera Pharmaceuticals INC. | $61.58 | 2022-2025 | Qinlock, Romvimza |
| Sumitomo Pharma America, INC. | $61.18 | 2024 | Orgovyx |
| Octapharma USA, INC. | $59.79 | 2022 | |
| Genmab U.S., INC. | $58.89 | 2023-2024 | Epkinly |
| Teva Pharmaceuticals USA, INC. | $56.98 | 2019 | |
| Karyopharm Therapeutics INC. | $56.79 | 2020-2023 | Xpovio |
| Adaptive Biotechnologies Corporation | $54.99 | 2024-2025 | Clonoseq |
| Pharmacosmos Therapeutics INC. | $51.65 | 2022-2025 | Monoferric |
| Seagen INC. | $51.59 | 2022-2023 | Adcetris, Padcev |
| Adc Therapeutics America, INC. | $50.04 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $48.23 | 2019-2023 | Ultomiris |
| Sanofi-Aventis U.S. LLC | $47.17 | 2019-2020 | |
| Springworks Therapeutics, INC. | $45.60 | 2024-2025 | Ogsiveo |
| Sanofi US Services INC. | $40.39 | 2025 | |
| Myovant Sciences INC. | $36.77 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $33.80 | 2019 | |
| Dendreon Pharmaceuticals LLC | $33.67 | 2022 | |
| Immunogen, INC. | $32.49 | 2023 | Elahere |
| Medtronic, INC. | $29.83 | 2025 | Osteocool Rf Ablation System |
| Servier Pharmaceuticals LLC | $29.29 | 2024 | |
| Cti Biopharma Corp. | $21.32 | 2023 | Vonjo |
| Agios Pharmaceuticals, INC. | $18.51 | 2025 | Pyrukynd |
| Caris Mpi, INC. | $17.58 | 2025 | Mi Cancer Seek |
| Dova Pharmaceuticals | $16.54 | 2019 | |
| Morphosys, US INC. | $15.43 | 2023 | Monjuvi |
| Tesaro, INC. | $15.12 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $14.66 | 2019 | |
| Spectrum Pharmaceuticals INC. | $13.20 | 2024 | Rolvedon |
| Puma Biotechnology, INC. | $12.46 | 2019 | |
| Coherus Oncology, INC. | $11.80 | 2022 | |
| Epizyme, INC. | $11.66 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Persing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.